EyePoint Pharmaceuticals (NASDAQ:EYPT) Raised to Sell at StockNews.com

StockNews.com upgraded shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) to a sell rating in a research note issued to investors on Friday.

Several other analysts have also commented on EYPT. Chardan Capital reaffirmed a “buy” rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Finally, Citigroup began coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 price target on the stock. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Stock Down 4.5 %

EyePoint Pharmaceuticals stock opened at $6.52 on Friday. The firm has a market cap of $448.11 million, a price-to-earnings ratio of -3.26 and a beta of 1.41. EyePoint Pharmaceuticals has a 52 week low of $5.54 and a 52 week high of $23.97. The business’s 50-day moving average price is $7.19 and its 200 day moving average price is $8.38.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10). The company had revenue of $11.60 million for the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. Equities analysts expect that EyePoint Pharmaceuticals will post -2.13 EPS for the current year.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Legal & General Group Plc lifted its position in shares of EyePoint Pharmaceuticals by 4.4% in the fourth quarter. Legal & General Group Plc now owns 46,263 shares of the company’s stock valued at $345,000 after acquiring an additional 1,932 shares in the last quarter. Summit Investment Advisors Inc. lifted its position in shares of EyePoint Pharmaceuticals by 39.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company’s stock valued at $51,000 after acquiring an additional 1,940 shares in the last quarter. Invesco Ltd. lifted its position in shares of EyePoint Pharmaceuticals by 16.1% in the fourth quarter. Invesco Ltd. now owns 15,657 shares of the company’s stock valued at $117,000 after acquiring an additional 2,177 shares in the last quarter. Teacher Retirement System of Texas lifted its position in shares of EyePoint Pharmaceuticals by 22.4% in the fourth quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company’s stock valued at $113,000 after acquiring an additional 2,782 shares in the last quarter. Finally, Swiss National Bank lifted its position in shares of EyePoint Pharmaceuticals by 3.5% in the fourth quarter. Swiss National Bank now owns 100,000 shares of the company’s stock valued at $745,000 after acquiring an additional 3,400 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.